Orthopedics Department, Southwest Hospital, The Army Military Medical University (The Third Military Medical University), Chongqing, China.
Asia Pac J Clin Oncol. 2023 Oct;19(5):e314-e319. doi: 10.1111/ajco.13916. Epub 2023 Jan 19.
To study the safety and efficacy of anlotinib, a multitargeted tyrosine kinase inhibitor, in the treatment of advanced osteosarcoma (OSS) with metastases.
We retrospectively studied patients with advanced OSS and metastases who received anlotinib treatment in our hospital from June 2018 to April 2020. All patients had received standard multimodal therapies, before taking anlotinib. Therapeutic doses of anlotinib were 12 mg for adults and 10 mg for children and adolescents once a day for 2 consecutive weeks, followed by a week of withdrawal. This 3-week cycle of treatment was continued until the tumor progressed rapidly or the patients failed to tolerate the side effects. Adverse drug reactions were recorded, and therapeutic efficacy was evaluated based on progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and objective response rate (ORR).
The median PFS was 9.8 ± .9 months, and the 6- and 10-month PFS rates were 73% and 33%, respectively. The median OS was 11.4 ± .6 months. No patients achieved complete response. After 6 months of treatment, the DCR and ORR were 80% and 13%, respectively. No drug-related deaths or Grade 4 adverse events occurred in the patients. Five patients (33%) had Grade 3 adverse events. The most common drug-related adverse events were hand-food syndrome, fatigue, high blood pressure, anorexia, and pneumothorax.
Anlotinib had a modest therapeutic effect in patients with advanced OSS after the failure of standard treatment. The adverse events were mostly tolerable or relieved after treatment.
研究多靶点酪氨酸激酶抑制剂安罗替尼治疗转移性晚期骨肉瘤（OSS）的安全性和有效性。
我们回顾性研究了 2018 年 6 月至 2020 年 4 月在我院接受安罗替尼治疗的转移性晚期 OSS 患者。所有患者在接受安罗替尼治疗前均接受了标准的多模式治疗。成人安罗替尼治疗剂量为 12mg，儿童和青少年为 10mg，每天一次，连续 2 周，然后停药 1 周。这种 3 周的治疗周期持续到肿瘤快速进展或患者无法耐受不良反应为止。记录不良反应，根据无进展生存期（PFS）、疾病控制率（DCR）、总生存期（OS）和客观缓解率（ORR）评估治疗疗效。
中位 PFS 为 9.8±0.9 个月，6 个月和 10 个月的 PFS 率分别为 73%和 33%。中位 OS 为 11.4±0.6 个月。无患者达到完全缓解。治疗 6 个月后，DCR 和 ORR 分别为 80%和 13%。患者无药物相关死亡或 4 级不良事件。5 名患者（33%）出现 3 级不良事件。最常见的药物相关不良事件是手足综合征、乏力、高血压、食欲减退和气胸。
在标准治疗失败后，安罗替尼对晚期 OSS 患者有一定的疗效。大多数不良反应在治疗后可耐受或缓解。
